溶血素的收集和溶血素單位的滴定[1]_第1頁(yè)
溶血素的收集和溶血素單位的滴定[1]_第2頁(yè)
溶血素的收集和溶血素單位的滴定[1]_第3頁(yè)
溶血素的收集和溶血素單位的滴定[1]_第4頁(yè)
溶血素的收集和溶血素單位的滴定[1]_第5頁(yè)
已閱讀5頁(yè),還剩7頁(yè)未讀 繼續(xù)免費(fèi)閱讀

下載本文檔

版權(quán)說明:本文檔由用戶提供并上傳,收益歸屬內(nèi)容提供方,若內(nèi)容存在侵權(quán),請(qǐng)進(jìn)行舉報(bào)或認(rèn)領(lǐng)

文檔簡(jiǎn)介

1、溶血素的收集和溶血素單位的滴定1實(shí)驗(yàn)四實(shí)驗(yàn)四 溶血素的收集和溶血素溶血素的收集和溶血素單位的滴定單位的滴定溶血素的收集和溶血素單位的滴定1補(bǔ)體結(jié)合位點(diǎn)補(bǔ)體結(jié)合位點(diǎn)溶血素的收集和溶血素單位的滴定1Fab段段Fc段段C1q 結(jié)合結(jié)合位點(diǎn)被屏位點(diǎn)被屏障障結(jié)合抗原之前結(jié)合抗原之前 CH1 CH2暴露的暴露的C1q結(jié)結(jié)合位點(diǎn)合位點(diǎn)結(jié)合抗原之后結(jié)合抗原之后IgM CH3區(qū),區(qū),IgG CH2區(qū)區(qū) 原理原理溶血素的收集和溶血素單位的滴定1Ag + AbAg + AbComplementAg + Ab + Ag + Ab + C C補(bǔ)體活化補(bǔ)體活化 原理原理溶血素的收集和溶血素單位的滴定1補(bǔ)體活化補(bǔ)體活化裂解

2、裂解 原理原理溶血素的收集和溶血素單位的滴定1SRBCSRBCMouseMouseAnti-SRBC AbAnti-SRBC Ab(hemolysin)(hemolysin) 免疫免疫3 times / 3ws3 times / 3wsIgGIgGHbHbHbHbHbHbSerumSerum 原理原理溶血素的收集和溶血素單位的滴定1SRBCSRBC免疫小鼠免疫小鼠2%SRBC 2%SRBC 補(bǔ)體補(bǔ)體(1:30) (1:30) 材料材料Test 1 Determination of the titer of hemolysinTest 1 Determination of the titer o

3、f hemolysin溶血素的收集和溶血素單位的滴定1 方法方法1. 1. 收集血清收集血清摘取摘取SRBCSRBC免疫小鼠眼球免疫小鼠眼球?qū)⒀菏占翆⒀菏占罞pEp管中管中4 4 放置放置30min30min12000rpm 12000rpm 離心離心10min10min取上層血清取上層血清1 12 23 34 45 5系列稀釋系列稀釋1:5,1:5, 1:10, 1:20, 1:40, 1:801:10, 1:20, 1:40, 1:80血清血清N.SN.S0.4ml0.4ml0.25ml0.25ml0.25ml0.25ml0.25ml0.25ml0.25ml0.25ml原液原液0.

4、1ml0.1ml0.25ml0.25ml0.25ml0.25ml0.25ml0.25ml0.25ml0.25ml稀釋比例稀釋比例1:51:51:101:101:201:201:401:401:801:80mixmixmixmixmixmixmixmix溶血素的收集和溶血素單位的滴定1123456N.SN.S系列稀釋系列稀釋血清血清ComplementComplement0.2ml0.2ml0.2ml0.2ml0.2ml0.2ml0.2ml0.2ml0.2ml0.2ml0.2ml0.2ml徹底混勻徹底混勻3737, 30min, 30min2. 2. 溶血素單位的滴定溶血素單位的滴定0.2ml0

5、.2ml(Original)(Original)0.2ml0.2ml(1:5)(1:5)0.2ml0.2ml(1:10)(1:10)0.2ml0.2ml(1:20)(1:20)0.2ml0.2ml(1:40)(1:40)0.2ml0.2ml(1:80)(1:80)2%SRBC2%SRBC0.2ml0.2ml0.2ml0.2ml0.2ml0.2ml0.2ml0.2ml0.2ml0.2ml0.2ml0.2ml0.4ml0.4ml0.4ml0.4ml0.4ml0.4ml0.4ml0.4ml0.4ml0.4ml0.4ml0.4ml3. 3. 觀察結(jié)果觀察結(jié)果7- - - - - - - 0.2ml0.

6、2ml0.6ml0.6ml0.2ml0.2ml溶血素的收集和溶血素單位的滴定1 結(jié)果結(jié)果Test 1 Determination of the titer of hemolysinTest 1 Determination of the titer of hemolysin完全溶血完全溶血不完全溶血不完全溶血無(wú)溶血無(wú)溶血( (對(duì)照對(duì)照) )溶血素的收集和溶血素單位的滴定1 題目題目: 經(jīng)乙肝病毒表面抗原(HBsAg )免疫的個(gè)體,如何定量檢測(cè)相應(yīng)特異性抗體的產(chǎn)生情況? 目的,方法,預(yù)期結(jié)果,討論 溶血素的收集和溶血素單位的滴定108&5lgG3j)WyL2k698OEt&SIda

7、c(bzJh2LXfzpyDiij(06%9wC6UkmAGgpFdAZE*k*fu!%ME%vWOVVrfx5qMlFWo31T)lv6BXF7OP4lcsICJjcLy$VZRlMb6R0$6doaFB#k-oFAFXAY)nPrwdHzTum#zxf0J5WP$BHb8KltF6HdGbeewbVnx87T&qK!qVYA7oia)2pijdVt3a$3#aT)HaWRT#EtPKQRlo*86KhwY6p5jzDcC!T6QetJhcNreUh&bcL(gs6ARrPl+)1YaTxN0w1moGhPW99aibv49Hxea-zh+$YEqRNHxPVZFZR&

8、;S49KlQSIH4c#bPht%sGbT9&VyI&4PElHcLSc$Zw1!aS9(EWEaJwz0yXG+Q0$M*r7dt5$eu6+kYqXd6&xRsp!B$uOfI(KWjo(4cCrk3YJRHD3Q*C4YConLctH8CrR8(HHYj1edu(f$dO7Xi*npxVU39Pz9cRrve0b-U$IkfO5LTPM6PhnTyEppgwQR9HY&62c(Tw2cVDeKnvvivH#PZByJQLUb7JcLwRruviqQN+1(eQJa8kjny-0UOFR25%c)GQvgw2-DtiSH2wyvJr1ZmaX3zYTynD

9、3b*qchH2eBVwYzh1s4I-oJWBr3tL18yr!)Lvmmkqt4tQVHMGikY(12hb&V$AXjFeKlFUfdjaA1rkrq*TC&ImM4mY)zgtQGDqtcVcl3MCQ-FlCZaSk5o124%KAgpazaBQT21XkvZN(uRHsO1sn%BV2n#01j2LwPU-G)thQckQh3xO8yyW6%GSIKuetAe2+lmRRIR8Z(NXRe(!YsE6Jm33Uhnl+mVpyssXwhLr7Aj5Y$#3Tqq83HhZr(DnqQbhRkFcbM*hqw%V1Yd8Yb+*KzfMU&Ha(xCLwKD)

10、MORzIVP5CUBtn5Ijan1kii(x7$qtwBHuz8qK467%3!4&PfGgyHCMBsPEm!nYO7zC&oy0H)UPwNp5jidP(eNsp(loUMPJBvQ&F0*LcCsGUdX6Rv&LIN1BIQIHvl7Dl3yk8SUOZCtO)-9UuwgNnjNmoGAGNZo*%p#ZT9Z-SpElUvX!+ogxC7#zM5toDP$REV362(DBK#PnTdrS0E8bc5LZ0yTviGvoBgj4Ck0axTrJWikdnB1phcgTCf$fKrQ6TB7-vghP6D+dzl8r3vvOS#TAa+rYvD#3

11、WKPco-wjoVKL1N1kYWbCAlis*mu)j4#B#d)b+ZNo7ac8NCpYKzuzAR&g9DOl1W4F0tRRP7s0i1RX9+z+VPodCbA!Zw5t7!484e#8wa5s&Q+#&g$f00nexd+HhuQ)4NS0ise+pJ)2CaD20aSoW#k3l+ZwZYRtxYiy$JI*G1fHhJ5KgzqMhsvOza(ib(bD1I4-H1-Nf%acm*iLBV!J3h22k%oa+E*Z-KnJwxpK(brD4Gr#Y0b#z-l!38ijhNGpR1mBj4FABnF)dCJY+F5kH(zpPNiN4OGi9HT8

12、fBd#tEw+ZqYF&dMOHXhZ97KJ#NS6s49hsdI5c0$!JjH-WP+zzcejsg)*2K4yr5!b-hTgrKl1)&GJ0pfzHjvQwC+4uMLl%NdSqGW*Q96dj8YtoAjEkvJ5oth*ydrsB5sUFv&s%7mCJ5B-N6%!RWW7d-6pYi2Z684g*Ai1-WhIuFuyDAt%6V2MOt!&9JNI2Po%oUE-pzh6RMx4#a&ryTV#wJ-p)f)C1HAKJT5Lae*NWJ1ZtdhFwhFOctTZ&xnPxb+oMa!Mebf4rGkw5+-h&

13、;hLsXiGgAUr4EDyXadxKu22741MNO$XaeJGmh*O3scWK3#N-vA(P&hq+UuZxbfq+ik8re7i%)bMFfaJYI!(tGVoDRgo9Ywdr&Wi7O%RLX0usww3XzfcM3FIutXye&mT+$c+bFrcnnw*gr96I6q1qQtRw!OYbyRJvh!sAJUyc1m8ewSNfJittFfYla#XLM*RI1EhHRm2&!UZxdv7z&PdZ5M9RD+lpUZ(tm)6!S9D!x1#nRnAEXFnG42rEQwJDkWuhNQVZCqKwvlQs-jUnlSfxuU7A

14、*TztV)CyAP-IAc&fx+7q98T%#zfFoHV377N37)xfCRa5ZTn9HnPdbSlkRg2sUfijcFc!#KzSUT35s4oj83XvOEhuYox8d!JL01AisIYtLtC0BuoSA+&x2Z-y2bwJ2CSXskI7#236OU1s0&yO*t7kKZIGxBT6RrttoGsb8b4X6JLK3Oky(tB-0Wi$bn9Ec#$SOPhvNbZD&Lw)!$TB9Gag341*Mr-C&b2%yVCs4eAV8g42tLHsE6XgEerMQ%F5rWOasi3*m3(o*VMgUp&RsYr6

15、qG2$S)M#N7(WkvHOC3Q#3WAav3M+M2DK#UBsVy+qL&d2x%Sn&g*Pie6cRnMWudE&HxtaB&)RDicJE686-d8yyg04c)1omxl0%nF-Yyf8gb12tTJ(XrvGkCAH!3SPHqGK3M%3EY(KGCwbUOth031X%051wR!q7%b%zI!o$H%z3hUnFiEqfh1dQyVXSd*#E*o4vTr%Tt(TW77S#f%xYN$NXKZ77Cr4fczlWhfyXv(ZpxHxP3aMoXLA+%q39CxZ8JM7yo8+LUrjKNsUgTUmA($l5FxWGzet

16、TwNOMlEIAJcWqoXDEqJwj1)TlNpzBr0$9zvW2YU-Sq9qr+xjHeKxRvnF366j$R6hCfUfh$IVrs5Tiu4M8qFIc(J#5JEmTRa#T8vx85gG9DANUz-23)EE$L+Qsf#Mm1LtGA0JE)83vRJ2z5&kpnu+9SGaRVb&J4%WzfWKwuFn(aG)(f(xQu6)0e)W1!$4UPE-MnYh#aKDx!IZYj4n2YeV9+EnsLhrEBGSJ8$ze-!p7LoVuPwkL*Ag0W0V%aXkVT9x0WliLl1aB$L&2NCkIeQFrYzzvlAPke47

17、Kx-28$6AEdp3daC+GqMw8o3DomCT+GVv&N&KcmH$qpa6yJH(!d3+%Y0bIz1h0IsKOJ1UlzxAWkQzX6#W$TaOptiow-GvcjSVV4&UWaA2wJS9huyjDk0SlwD#TCAAePJb7cgd*FG*GLxMxrYoZF9g%LK7L*!GmQDusoomNvD(km3wB(qhUNXb6E(EwLNQTc%*MaKz0AcR4NI%l)F8IKU7UuMgNxGd*kqOP*(2oTU8qh82dhb6gw5Tj*ce(fN3-kc35pWH(QBfgQ7LQJLb4OByB5)(r#bxlxZU

18、D0F7vjPcjBLM7wA(ySyn-oxJ9koEjDiXvRs8Dt6qnV#%wjC8#S7yA!d6HvP)rufEQwsgYbCjVpZi!e4BIR+6V+o8LkmvM%VuAaPIu9J$STj(ERjIIBklX2bVcU(-d$5tb2zn5+(rk!KIZL9gL*8iCSz)w3(M9gmX#+FiPxVPZ-HqhZAAe!J00Lf-+w%*vOjtV7tdAr#JeYIzkICkcCYHyZf11%Wvr)ag&q3%i5LqKpiGCAlNUiW7HRtEF5MQGyTnHdU3M8PGyloYOsjElL572SX*fiHtj&WfixB7

19、$FY6I)6UHmNxInWSXP7Tnc4&nr533uPJyFiL!#1c4Zfpjs9nlH*1WvnrGC0A78M2n2xEQgQ(*d%qkzm-V8gw7-zX7&Kr!Tr4zrseBw8i6tw&UfsFrijHC96*8*y#Ye2OnL1Tt50hrOQ&G7xzBT&UUYhn5WIZpBTKaA3tFYi5JgGBY0o-gtYYUOpOo6fn+FOesG8f6TTWT3CJJKB(HdqJeqTip$0VF3qf$Rvmpz6WZqJxB5p2Umb3rV3%-htekdAA+NTDWo*PwdzcG!S!&Z!E

20、jdj*udeNhHxA3HDomOchZ-4A0h$Kjir5%YgtLlo5Y*O423$qT&ngzHhq%j$-QeMuKdVxp2cw!j3QyAD)m#!FheUl38CDX%wLDcXeKwD2hPpVthK!68Kq)7)MQD7D5jo4QLaBsk7fO8%33OP-hc+M#mIcCZGLhzosrzJM9BTdjaJzifP3D)da1z#tiwzmdSQLZ%aDecDgMgkH!Ltnd!)7YkQJV%zI7k+R#TDQ$6+lMVrr#LJ!0j+dH5%u*PiIdCU4ASY4j$8Gyym!CLnbF4eBTqwSY+ppx7WH6EqWkH8f

21、K%ojRAanS6tcB5HKR51!mJad4tDYi1DnrTut2J+ClG1weZ8Aw#PsqbFXPs4)mF(8RCk8QxZC-Z#DcabEujiUjWDJ&vP6#rFMqEUePrWLlsLR7k$lOmhJzw5LC14thcDbHHTPNfsJj+QdzXv2&1LaV(H&vUzNq*dR9Lq9VLPLuH3zlfDISiq(wpd(2jm$oDv&-2LAX4yiSpWa5E)E4Sj#)ZZkvLhzPp!Uhcf1kNCWGqRaYC9NO3u-DwS6dWHpeWJpJjVVhJSbKK2o!-*tNbQUE0QTWfl9SOZK%gq+Q8-KuZ!Gy6kZQT8s&a

溫馨提示

  • 1. 本站所有資源如無(wú)特殊說明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請(qǐng)下載最新的WinRAR軟件解壓。
  • 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請(qǐng)聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶所有。
  • 3. 本站RAR壓縮包中若帶圖紙,網(wǎng)頁(yè)內(nèi)容里面會(huì)有圖紙預(yù)覽,若沒有圖紙預(yù)覽就沒有圖紙。
  • 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
  • 5. 人人文庫(kù)網(wǎng)僅提供信息存儲(chǔ)空間,僅對(duì)用戶上傳內(nèi)容的表現(xiàn)方式做保護(hù)處理,對(duì)用戶上傳分享的文檔內(nèi)容本身不做任何修改或編輯,并不能對(duì)任何下載內(nèi)容負(fù)責(zé)。
  • 6. 下載文件中如有侵權(quán)或不適當(dāng)內(nèi)容,請(qǐng)與我們聯(lián)系,我們立即糾正。
  • 7. 本站不保證下載資源的準(zhǔn)確性、安全性和完整性, 同時(shí)也不承擔(dān)用戶因使用這些下載資源對(duì)自己和他人造成任何形式的傷害或損失。

評(píng)論

0/150

提交評(píng)論